Selected article for: "complement system and microarray analysis"
Author: Zhou, Ping; Zhai, Shanli; Zhou, Xiang; Lin, Ping; Jiang, Tengfei; Hu, Xueying; Jiang, Yunbo; Wu, Bin; Zhang, Qingde; Xu, Xuewen; Li, Jin-ping; Liu, Bang
Title: Molecular Characterization of Transcriptome-wide Interactions between Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus and Porcine Alveolar Macrophages in vivo
  • Document date: 2011_8_7
    • ID: js7l86fh_40
    Snippet: In summary, the data presented in this study suggested that during infection with HP-PRRSV Tongcheng piglets exhibited typical clinical signs, but displayed mild regional lung damage at 5 and 7 dpi. Microarray analysis revealed that HP-PRRSV infection has affected PAMs in vivo in expression of the important genes involved in cytoskeleton and exocytosis organization, protein degradation and folding, intracellular calcium and zinc homeostasis. Seve.....
    Document: In summary, the data presented in this study suggested that during infection with HP-PRRSV Tongcheng piglets exhibited typical clinical signs, but displayed mild regional lung damage at 5 and 7 dpi. Microarray analysis revealed that HP-PRRSV infection has affected PAMs in vivo in expression of the important genes involved in cytoskeleton and exocytosis organization, protein degradation and folding, intracellular calcium and zinc homeostasis. Several potential antiviral strategies might be employed in PAMs, including upregulating IFN-induced genes and increasing intracellular zinc ion concentration. Furthermore, inhibition of the complement system likely attenuated the lung damage during HP-PRRSV infection. This system analysis could lead to a better understanding of the HP-PRRSV-host interaction, and to the identification of novel antiviral therapies and identifying genetic components for swine tolerance/susceptibility to HP-PRRS.

    Search related documents:
    Co phrase search for related documents
    • antiviral strategy and lung damage: 1, 2, 3
    • antiviral strategy and novel antiviral therapy: 1
    • antiviral strategy and potential antiviral strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • antiviral strategy and protein degradation: 1, 2, 3, 4
    • antiviral strategy and PRRSV host: 1
    • antiviral strategy and study present: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • antiviral strategy and zinc homeostasis: 1, 2
    • antiviral therapy and clinical sign: 1
    • antiviral therapy and complement system: 1, 2
    • antiviral therapy and IFN induce: 1, 2
    • antiviral therapy and important gene: 1, 2
    • antiviral therapy and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • antiviral therapy and microarray analysis: 1
    • antiviral therapy and novel antiviral therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • antiviral therapy and novel antiviral therapy identification: 1, 2, 3
    • antiviral therapy and potential antiviral strategy: 1, 2
    • antiviral therapy and protein degradation: 1, 2
    • antiviral therapy and study present: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • antiviral therapy and system analysis: 1, 2